Natera Additional Paid-in Capital 2014-2026 | NTRA
Natera additional paid-in capital from 2014 to 2026. Additional paid-in capital can be defined as the excess over par value paid for common securities.
- Natera additional paid-in capital for the quarter ending March 31, 2026 was $4.635B, a 19.63% increase year-over-year.
- Natera additional paid-in capital for 2025 was $4.489B, a 19.27% increase from 2024.
- Natera additional paid-in capital for 2024 was $3.764B, a 19.64% increase from 2023.
- Natera additional paid-in capital for 2023 was $3.146B, a 18.05% increase from 2022.
|
Natera Annual Additional Paid-in Capital (Millions of US $) |
|
|---|---|
| 2025 | $4,489 |
| 2024 | $3,764 |
| 2023 | $3,146 |
| 2022 | $2,665 |
| 2021 | $2,050 |
| 2020 | $1,411 |
| 2019 | $977 |
| 2018 | $607 |
| 2017 | $473 |
| 2016 | $453 |
| 2015 | $436 |
| 2014 | $9 |
| 2013 | $3 |
|
Natera Quarterly Additional Paid-in Capital (Millions of US $) |
|
|---|---|
| 2026-03-31 | $4,635 |
| 2025-12-31 | $4,489 |
| 2025-09-30 | $4,076 |
| 2025-06-30 | $3,982 |
| 2025-03-31 | $3,875 |
| 2024-12-31 | $3,764 |
| 2024-09-30 | $3,393 |
| 2024-06-30 | $3,320 |
| 2024-03-31 | $3,241 |
| 2023-12-31 | $3,146 |
| 2023-09-30 | $3,089 |
| 2023-06-30 | $2,796 |
| 2023-03-31 | $2,742 |
| 2022-12-31 | $2,665 |
| 2022-09-30 | $2,181 |
| 2022-06-30 | $2,140 |
| 2022-03-31 | $2,090 |
| 2021-12-31 | $2,050 |
| 2021-09-30 | $2,012 |
| 2021-06-30 | $1,400 |
| 2021-03-31 | $1,356 |
| 2020-12-31 | $1,411 |
| 2020-09-30 | $1,384 |
| 2020-06-30 | $1,093 |
| 2020-03-31 | $988 |
| 2019-12-31 | $977 |
| 2019-09-30 | $748 |
| 2019-06-30 | $733 |
| 2019-03-31 | $614 |
| 2018-12-31 | $607 |
| 2018-09-30 | $600 |
| 2018-06-30 | $492 |
| 2018-03-31 | $476 |
| 2017-12-31 | $473 |
| 2017-09-30 | $467 |
| 2017-06-30 | $461 |
| 2017-03-31 | $456 |
| 2016-12-31 | $453 |
| 2016-09-30 | $448 |
| 2016-06-30 | $445 |
| 2016-03-31 | $440 |
| 2015-12-31 | $436 |
| 2015-09-30 | $433 |
| 2015-06-30 | $12 |
| 2015-03-31 | $0 |
| 2014-12-31 | |
| 2014-09-30 | $0 |
| 2014-06-30 | $0 |
| 2013-12-31 | $3 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $32.768B | $2.306B |
| Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVS Health (CVS) | United States | $129.251B | 14.33 |
| Danaher (DHR) | United States | $126.118B | 22.33 |
| Elevance Health (ELV) | United States | $85.740B | 12.83 |
| HCA Healthcare (HCA) | United States | $83.631B | 13.02 |
| Cencora (COR) | United States | $52.781B | 16.27 |
| Labcorp Holdings (LH) | United States | $20.863B | 15.10 |
| Viatris (VTRS) | United States | $17.911B | 6.28 |
| DiDi Global (DIDIY) | China | $16.365B | 25.64 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.375B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $13.258B | 54.19 |
| Medpace Holdings (MEDP) | United States | $13.014B | 28.64 |
| Solventum (SOLV) | United States | $12.739B | 11.79 |
| Revvity (RVTY) | United States | $11.049B | 19.34 |
| ICON (ICLR) | Ireland | $10.775B | 12.49 |
| BioMerieux (BMXMF) | France | $9.232B | 0.00 |
| Charles River Laboratories (CRL) | United States | $8.745B | 18.16 |
| HealthEquity (HQY) | United States | $7.074B | 23.57 |
| Sonic Healthcare (SKHHY) | Australia | $6.895B | 0.00 |
| Avantor (AVTR) | United States | $6.384B | 11.00 |
| PACS (PACS) | United States | $5.978B | 24.21 |
| GETINGE (GNGBY) | Sweden | $5.438B | 17.36 |
| Bausch + Lomb (BLCO) | Canada | $5.331B | 22.97 |
| CochLear (CHEOY) | Australia | $5.195B | 0.00 |
| Caris Life Sciences,�Inc (CAI) | United States | $4.893B | 0.00 |
| Sotera Health (SHC) | United States | $4.489B | 19.92 |
| Alignment Healthcare (ALHC) | United States | $4.401B | 236.56 |
| Concentras Parent (CON) | United States | $3.646B | 19.78 |
| Organon (OGN) | United States | $3.519B | 4.27 |
| Establishment Labs Holdings (ESTA) | United States | $2.533B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 13.19 |
| Progyny (PGNY) | United States | $2.059B | 34.13 |
| Pediatrix Medical (MD) | United States | $1.932B | 11.59 |
| Surgery Partners (SGRY) | United States | $1.903B | 58.20 |
| Agilon Health (AGL) | United States | $1.887B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.732B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $1.704B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.645B | 65.20 |
| Teladoc Health (TDOC) | United States | $1.368B | 0.00 |
| Ardent Health (ARDT) | United States | $1.294B | 5.51 |
| CareDx (CDNA) | United States | $1.294B | 0.00 |
| InnovAge Holding (INNV) | United States | $1.250B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.240B | 0.00 |
| Omada Health (OMDA) | United States | $1.069B | 0.00 |
| Nutex Health (NUTX) | United States | $1.033B | 11.60 |
| GoodRx Holdings (GDRX) | United States | $0.880B | 16.06 |
| CryoPort (CYRX) | United States | $0.744B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Strata Critical Medical (SRTA) | United States | $0.498B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| Oncology Institute (TOI) | United States | $0.495B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.389B | 4.74 |
| Shoulder Innovations (SI) | United States | $0.369B | 0.00 |
| Forward Industries (FWDI) | United States | $0.319B | 0.00 |
| SBC Medicals (SBC) | United States | $0.303B | 7.56 |
| LifeMD (LFMD) | United States | $0.208B | 0.00 |
| Embecta (EMBC) | United States | $0.180B | 1.17 |
| Biodesix (BDSX) | United States | $0.180B | 0.00 |
| So-Young (SY) | China | $0.159B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.100B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.087B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.086B | 14.28 |
| Park Dental Partners (PARK) | United States | $0.082B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.072B | 0.00 |
| DocGo (DCGO) | United States | $0.053B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.028B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.017B | 0.00 |
| Ainos (AIMD) | United States | $0.016B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Pomdoctor - (POM) | China | $0.011B | 0.00 |
| XWELL (XWEL) | United States | $0.010B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |